drugset / Trial / NCT00422617

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

NCT00422617

Completed 40 enrolled Uni-Pharma Biogen · collab
Non-randomizedSingle-groupOpen-labelEct

Summary

An open-label, multicentre study to evaluate the efficacy and safety of one course of weekly intramuscular administration of Amevive in Taiwan patients with chronic plaque psoriasis

Timeline

Start
2005-01
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 15 mg Intramuscular

Indications